CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved January 23, 2026, to 11 new employees totaling 31,428 restricted stock units.

One-fourth of each award vests on February 16, 2027, then one-twelfth of the remaining shares vests quarterly thereafter, subject to continued employment. Awards were granted under the Amended and Restated 2019 Inducement Equity Plan.

News Market Reaction

-0.49%

1 alert

-0.49% News Effect

On the day this news was published, BBIO declined 0.49%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (Nasdaq: BBIO), please note that some of the figures in the first paragraph were incorrect. The corrected release follows:

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on January 23, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 11 new employees in restricted stock units for an aggregate of 31,428 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on February 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”).

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, and YouTube.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com 

FAQ

What did BridgeBio (BBIO) grant to new employees on January 23, 2026?

BridgeBio granted 31,428 restricted stock units to 11 new employees as inducement awards. According to the company, the grants were approved by the compensation committee and made under the company’s inducement equity plan.

When do the restricted stock units for BBIO new hires begin vesting?

One-fourth of each employee’s restricted stock units vests on February 16, 2027. According to the company, the remainder vests in one-twelfth increments quarterly thereafter, subject to continued employment.

Under which plan were BBIO inducement awards granted and when was it adopted?

The awards were granted under the Amended and Restated 2019 Inducement Equity Plan. According to the company, the plan was adopted in November 2019 and amended in February and December 2023.

How many employees received inducement RSU awards from BridgeBio (BBIO)?

The company approved inducement restricted stock unit awards for 11 new employees. According to the company, the awards were deemed material inducements to the employees entering employment.

Do BBIO inducement awards require continued employment to vest?

Yes, each vesting event is conditioned on the employee’s continued employment with BridgeBio or a subsidiary. According to the company, vesting dates are subject to that continued employment requirement.

Why did BridgeBio issue a correcting release about the BBIO inducement grants?

BridgeBio corrected earlier figures in the initial release and provided the accurate inducement award details. According to the company, the corrected release replaces incorrect figures from the earlier issuance.